Skip to main content
. Author manuscript; available in PMC: 2017 Mar 1.
Published in final edited form as: J Clin Virol. 2016 Jan 2;76:8–13. doi: 10.1016/j.jcv.2015.12.011

Table 2.

a: Results of 24 HIV-infected participants with discordant point-of-care HIV test results
Last neg
HIV test		 OraQuick
OF		 OraQuick
FS		 Uni-Gold INSTI Determine 3rd or 4th gen
EIA1 		Western blot band pattern HIV RNA
(copies/mL)
Ag Ab
1 2 mo — — — ND + — 3rd — Negative 5.8 million
2 4 yr + + — ND ND 3rd + 24, 31, 40, 55, 120 141,000
3 2 yr — + + ND ND 3rd + 24, 31, 40, 55, 160 128,000
4 2 yr — + + ND ND 3rd + 18, 24, 31, 40, 51, 55, 120, 160 25,000
5 NA — — + ND ND 3rd + 24, 51, 55, 160 12.8 million
6 NA — — + ND — + 3rd + 24, 40, 55, 160 21,000
7 1 yr — + — ND — + 4th Ab+ 24, 51, 55 719,000
8 1 yr — + + ND — + 4th Ab+ 24, 31, 55, 160 436,000
9 6 mo — + + ND — + 4th Ab+ 24, 55, 160 33,000
10 2 mo — + + ND — + 4th Ab+ 24, 55, 160 9000
11 3 mo — + + ND — + 4th Ab+ 18, 24, 55, 160 32,000
12 2 mo — + + ND — + 4th Ab+ 24, 160 94,000
13 2 mo — — + ND — + 3rd + 18, 24, 31, 41, 51, 55, 65, 120, 160 ND
14 2 yr — — + ND — + 3rd + 18, 24, 31, 40, 51, 55, 65, 120, 160 ND
15 4 mo — — ND + — + 3rd + 24, 55, 160 ND
16 3 mo — — ND + — + 3rd + 24, 51, 55, 160 347,000
17 7 mo — — ND + — + 3rd + 18, 24, 65, 160 110,000
18 5 mo — — ND + — + 3rd + 24, 51, 55, 160 62,000
19 4 mo — + ND + — + 3rd + 18, 24, 31, 41, 51, 55, 65, 120, 160 7000
20 8 mo — + ND + — + 4th Ab+ 24, 51, 55, 65, 120, 160 70,000
21 NA — + ND + — + 4th Ab+ 24, 55, 160 7000
22 2 mo — + ND + — + 4th Ab+ Negative 323,000
23 2 mo — + ND + — + 4th Ab+ 160 316,000
24 NA — — ND + — + 4th Ag+ 24 4.4 million
b: Results of 16 HIV-infected participants with antibody-negative/NAAT-Positive or POC-negative/EIA-positive HIV test results1
Last neg
HIV test		 OraQuick
OF		 OraQuick
FS		 Uni-Gold INSTI Determine 3rd or 4th gen
EIA2 		Western blot band pattern HIV RNA
(copies/mL)
Ag Ab
1 7 mo — — — ND — — 3rd + Negative 9.0 million
2 8 mo — — — ND — — 3rd + Negative 587,000
3 5 mo — — — ND — — 3rd + 18, 41, 51 ND
4 8 mo — — NA NA — — 3rd + Negative 5.8 million
5 NA — — — ND ND 3rd + NA NA
6 2 mo — — ND — — — 3rd + Negative 8.5 million
7 6 mo — — — ND ND 3rd — ND 5.4 million
8 1 yr — — — ND ND 3rd — ND >10 million
9 3 mo — — — ND ND 3rd — ND 59,000
10 1.5 mo — — — ND ND 3rd — ND >10 million
11 2 yr — — — ND ND 3rd — ND 306,000
12 2 mo — — — ND — — 3rd — ND 25,000
13 3 mo — — ND — — — 3rd — ND 8,000
14 4 mo — — ND — — — 3rd — ND 1.1 million
15 NA — — — ND — — 4th Ag+ negative 33,000
16 NA — — ND — — — 4th Ag+ negative 72,000

OF: oral fluids; FS: fingerstick; Ag: antigen; Ab: antibody; EIA: enzyme immunoassay; ND: not done; NA: not available

Results from participants #1–12 were previously reported [Stekler, J Clin Virol, 2013]

1

The ARCHITECT assay was considered to be reactive for antibody if the Multispot HIV-1/HIV-2 Rapid Test, performed for confirmatory testing, was reactive. It was considered to be reactive for p24 antigen if the Multispot was non-reactive.

1

The participant with acute HIV infection who had a reactive Determine Combo is shown as #1 in Table 2a.

2

The ARCHITECT assay was considered to be reactive for p24 antigen if the Multispot was non-reactive.